6505--Oxybutynin CL SA Tablets

The Department of Veterans Affairs National Acquisition Center is soliciting proposals for the supply of Oxybutynin Chloride Sustained-Release Tablets in 5mg and 10mg strengths, packaged in bottles of 100 and 500 tablets. This pharmaceutical contract will serve the VA, Department of Defense, Indian Health Service, Bureau of Prisons, and Federal Health Care Center. Offerors must submit pricing for all five line items across a base year and four one-year option periods, with proposals due by November 5, 2025, at 2:30 PM CT. A critical requirement is that each offeror must provide an 11-digit National Drug Code number specific to their company, and non-manufacturers must submit a Letter of Commitment from the manufacturer. The contract includes a mandatory 0.5% Cost Recovery Fee that must be incorporated into pricing. The evaluation criteria prioritize competitive pricing and compliance with all submission requirements, including the NDC specification and manufacturer documentation.

This solicitation has no set-aside designation and represents a single aggregate award opportunity. The current prime vendors for pharmaceutical distribution include McKesson Corporation and other established pharmaceutical prime vendors through which the contract will be distributed. Total estimated annual usage ranges from 11,309 to 30,276 bottles depending on strength and package size, indicating a significant supply requirement across the five-year contract period. The anticipated contract period spans one base year with four optional one-year renewals, providing stability for the selected vendor. While specific dollar values are not stated in the solicitation notice, the volume requirements and multiple government agencies involved suggest a substantial annual procurement. The contract will serve federal healthcare facilities nationwide, with distribution managed through established pharmaceutical prime vendor networks.